Telix Pharmaceuticals (TLX) Price & Analysis

Compare

323 Followers

TLX Stock Chart & Stats

Day’s Range― - ―

52-Week RangeAU$16.76 - AU$31.97

Previous CloseN/A

Volume456.62K

Average Volume (3M)1.30M

Market Cap

$8.66B

Enterprise ValueAU$2.15B

Total Cash (Recent Filing)$710.35M

Total Debt (Recent Filing)AU$581.45M

Price to Earnings (P/E)169.5

Beta1.35

Next Earnings

Aug 21, 2025

EPS Estimate

0.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.06

Shares Outstanding338,248,780

10 Day Avg. Volume1,064,220

30 Day Avg. Volume1,303,167

Financial Highlights & Ratios

PEG Ratio-1.26

Price to Book (P/B)28.23

Price to Sales (P/S)0.00

P/FCF Ratio-29.02

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$35.13

Price Target Upside37.22% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Telix Pharmaceuticals News

PremiumCompany Announcements

Telix Pharmaceuticals Hosts Investor Day in New York City

7d ago

PremiumCompany Announcements

Telix Pharmaceuticals Issues New Securities to Bolster Strategic Initiatives

13d ago

PremiumCompany Announcements

Telix Pharmaceuticals to Quote New Securities on ASX

13d ago

PremiumCompany Announcements

Telix Pharmaceuticals Issues New Equity Securities for Employee Incentives

13d ago

PremiumCompany Announcements

Telix Pharmaceuticals Issues New Share Appreciation Rights

13d ago

PremiumCompany Announcements

Telix Pharmaceuticals Announces Director Change

27d ago

PremiumCompany Announcements

Telix Pharmaceuticals’ AGM Resolutions Successfully Passed

28d ago

PremiumCompany Announcements

Telix Pharmaceuticals Expands Global Reach with Product Approvals

28d ago

See All AU:TLX News

See All News >

Bulls Say, Bears Say

Bulls Say

EarningsTelix reported Q1 total revenue of $186MM (AU$296MM, +31% Q/Q, +62% Y/Y), which could lead to an H1 beat as consensus currently estimates AU$547MM (vs the current H1 run-rate of AU$592).

Market ExpansionIlluccix received a positive decision on the MAA in Europe and country approvals in Denmark, Ireland, Luxembourg, Malta, the Netherlands, Norway, and Sweden as well as MAA approval in the UK and Brazil.

Product ApprovalsApprovals of Zircaix and Pixclara and Illuccix reimbursement decisions ex-US could lead to increased revenue.

Bears Say

Product Revenue DelayZircaix revenue is delayed to the second half of 2025 due to the NDA resubmission requirement.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

6.64% Insiders

2.92%

Mutual Funds

― Other Institutional Investors

86.26% Public Companies and

Individual Investors

Detailed Ownership Overview >

TLX FAQ

What was Telix Pharmaceuticals Ltd.’s price range in the past 12 months?

Telix Pharmaceuticals Ltd. lowest share price was AU$16.76 and its highest was AU$31.97 in the past 12 months.

What is Telix Pharmaceuticals Ltd.’s market cap?

Telix Pharmaceuticals Ltd.’s market cap is $8.66B.

When is Telix Pharmaceuticals Ltd.’s upcoming earnings report date?

Telix Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 21, 2025 which is in 65 days.

How were Telix Pharmaceuticals Ltd.’s earnings last quarter?

Telix Pharmaceuticals Ltd. released its earnings results on Feb 20, 2025. The company reported AU$0.06 earnings per share for the quarter, the consensus estimate of AU$0.06 by AU$0.

Is Telix Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Telix Pharmaceuticals Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Telix Pharmaceuticals Ltd. pay dividends?

Telix Pharmaceuticals Ltd. does not currently pay dividends.

What is Telix Pharmaceuticals Ltd.’s EPS estimate?

Telix Pharmaceuticals Ltd.’s EPS estimate is 0.27.

How many shares outstanding does Telix Pharmaceuticals Ltd. have?

Telix Pharmaceuticals Ltd. has 338,248,780 shares outstanding.

What happened to Telix Pharmaceuticals Ltd.’s price movement after its last earnings report?

Telix Pharmaceuticals Ltd. reported an EPS of AU$0.06 in its last earnings report, expectations of AU$0.06. Following the earnings report the stock price went down -1.342%.

Which hedge fund is a major shareholder of Telix Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in AU:TLX

Telix Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

14.52%

Trailing 12-Months

Asset Growth

244.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Telix Pharmaceuticals Ltd.

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials and TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; scientific and clinical research collaboration with Mauna Kea Technologies; and strategic collaboration agreement with Lightpoint Medical, Ltd. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

TLX Company Deck

TLX Earnings Call

Q4 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects strong financial performance and strategic growth through acquisitions and R&D investments. Despite potential regulatory delays and market uncertainties, Telix is well-positioned for significant expansion with an innovative product pipeline.Read More>

TLX Stock 12 Month Forecast

Average Price Target

AU$35.13

▲(37.22%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"17":"AU$17","22":"AU$22","27":"AU$27","32":"AU$32","37":"AU$37"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":36.228266290656,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$36.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.1285887304,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$35.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.215584830064,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$34.22</span>\n  </div></div>","useHTML":true}}],"tickPositions":[17,22,27,32,37],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.05,26.832943560819693,27.615887121639386,28.398830682459078,29.18177424327877,29.964717804098463,30.747661364918155,31.530604925737848,32.313548486557536,33.09649204737723,33.87943560819693,34.66237916901662,35.445322729836306,{"y":36.228266290656,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.05,26.74835297926154,27.446705958523076,28.145058937784615,28.843411917046154,29.54176489630769,30.24011787556923,30.93847085483077,31.636823834092304,32.33517681335385,33.03352979261538,33.73188277187692,34.430235751138454,{"y":35.1285887304,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.05,26.678121910004926,27.306243820009847,27.934365730014772,28.562487640019693,29.190609550024618,29.81873146002954,30.446853370034464,31.074975280039386,31.70309719004431,32.33121910004923,32.95934101005415,33.58746292005908,{"y":34.215584830064,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.15,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.09,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.97,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.45,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.46,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >